Overview

Iguratimod in Systemic Sclerosis

Status:
Not yet recruiting

Trial end date:
2024-01-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of iguratimod in adult subjects with diffuse cutaneous systemic sclerosis.

Phase:

N/A

Details

Lead Sponsor:

RenJi Hospital